UBS raised the firm’s price target on Gilead (GILD) to $112 from $108 and keeps a Neutral rating on the shares. Gilead reported a strong quarter commercially and UBS is optimistic on the launch of Yeztugo for PrEP, the analyst tells investors in a research note. The firm thinks Gilead will continue to show strong demand growth from the core HIV franchise and thinks Yeztugo could be a meaningful source of growth in the medium- to long-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead upgraded to Buy from Hold at Truist
- Gilead Sciences: Strong Q2 Performance and Promising Outlook Drive Buy Rating
- Gilead Sciences Reports Strong Q2 2025 Results
- Gilead Sciences: Strong Financial Performance and Positive Outlook Justify Buy Rating
- Closing Bell Movers: Expedia, TripAdvisor jump on Q2 earnings beats